RWP
NVO

Revolve Wealth Partners’s Novo Nordisk NVO Stock Holding History

Revolve Wealth Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,490
Closed -$214K – 237
2024
Q4 		$214K Buy
2,490
+200
+9% +$21.6K 0.03% 204
2024
Q3 		$273K Buy
+2,290
New +$305K 0.04% 161

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Revolve Wealth Partners's NVO Position: Q1 2025 in Review

Revolve Wealth Partners sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,490 shares — an estimated $214K sold.

Revolve Wealth Partners first reported a position in NVO in Q3 2024 and held it in 2 quarters. The position peaked at $273K in Q3 2024. 1,531 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Revolve Wealth Partners reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Revolve Wealth Partners sold 2,490 Novo Nordisk shares in Q1 2025, an estimated $214K.
  • Revolve Wealth Partners first reported a position in Novo Nordisk in Q3 2024 and held it in 2 quarters.
  • Revolve Wealth Partners's Novo Nordisk position peaked at $273K in Q3 2024.
  • 1,531 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Revolve Wealth Partners's 13F filing for Q1 2025, filed 14 Apr 2025.